Impiricus, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Impiricus, Inc. - overview
Established
2020
Location
Atlanta, GA, US
Primary Industry
Healthcare IT
About
Founded in 2020, and based in Georgia, US, Impiricus, Inc. , also known as ImpiricusHealth Corp. , operates as a medical technology firm that offers pharmaceutical companies a variety of tools to engage with HCPs. The company was founded by its CPO, Osama Hashmi, and CEO, Sandy Donaldson.
In April 2022, Impiricus, Inc. raised USD 3 million in seed funding led by FCA Venture Partners and Surface Ventures. Impiricus provides an artificial intelligence-based (healthcare professionals) HCP Engagement platform, an API-centric HealthTech platform that connects healthcare professionals to streamline their workflows and deliver better care to their patients, allowing patients to receive medical and pharmacy benefit information related to their condition. The platform allows medical and marketing teams to engage KOLs, and they have partnered with digital therapeutic companies to provide medical devices to improve patient outcomes.
Current Investors
Johnson Venture Partners, Surface Ventures, FCA Venture Partners
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT, Application Integration Software
Website
www.impiricus.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.